Syndax Pharmaceuticals Strategy and Business Model

Executive Overview

Syndax Pharmaceuticals is a Waltham, Massachusetts-based biopharmaceutical company founded in 2005 that focuses on targeted cancer therapies and treatments for serious immune-mediated disease linked to transplantation. After spending most of its history as a clinical-stage biotech, Syndax moved into a new phase in 2024 with U.S. approvals for Revuforj (revumenib), an oral menin inhibitor for a genetically defined acute leukemia population, and Niktimvo (axatilimab-csfr), an antibody for chronic graft-versus-host disease after multiple prior systemic therapies. FY2024 revenue was #N/A, reflecting a transition year rather than a fully scaled commercial base. Syndax operates in specialty hematology, oncology, and transplant-related immunology, where patient populations are small, treatment centers are concentrated, and strong clinical data can support premium pricing and focused commercial teams. Its footprint is primarily U.S.-centered for commercialization, while development programs, clinical trial sites, and partnerships give it broader international reach. Strategically, Syndax is trying to convert two mechanism-driven assets into durable franchises through disciplined launch execution, additional indications, and selective partnering rather than by building a broad, mass-market pharmaceutical platform.

Syndax Pharmaceuticals at a Glance

Logo
Common name	Syndax
Full legal name	Syndax Pharmaceuticals, Inc.
Headquarters	Waltham, Massachusetts, United States
Ownership	Public company; Nasdaq-listed common stock
Ticker	SNDX
Exchange	NASDAQ
Market Cap	$1.74B
Revenue (FY2024)	#N/A
Founding / major historical milestones	Founded in 2005; initial public offering in 2015; strategic reset in the early 2020s toward hematologic malignancies and chronic graft-versus-host disease; first U.S. product approvals in 2024
Industry or industries	Biotechnology; oncology; hematology; transplant-related immunology
Key products or services	Specialty prescription medicines, including Revuforj (revumenib) and Niktimvo (axatilimab-csfr), plus lifecycle development of additional indications
Geographic footprint	Primarily U.S.-focused commercialization with international clinical-development activity and partner-enabled reach
Business segments as officially reported	One operating and reportable segment
Company website	https://www.syndax.com

1. What Is the Strategy of Syndax?

Based on Syndax’s annual-report language, investor materials, and launch-era messaging, the company’s strategy is to build a focused specialty biopharma franchise around a small number of differentiated assets rather than to operate as a broad therapeutic-area conglomerate. The clearest way to describe that strategy is through the Playing to Win framework.

1. 1a. What is the winning aspiration of Syndax?

   Syndax’s winning aspiration is to develop and commercialize therapies that materially improve outcomes in serious, underserved hematologic cancers and chronic graft-versus-host disease. In practical terms, “winning” means turning scientific differentiation into regulatory approvals, successful launches, and durable label expansion. The company has not centered public communication on a single long-term revenue or margin target. Instead, its stated ambition has been product-focused: establish Revuforj and Niktimvo in their approved uses, broaden those franchises through additional indications, and become a sustainable commercial-stage biotech built around hematology and transplant-related disease.

2. 1b. Where does Syndax play?

   Syndax has chosen to play in narrow, high-unmet-need specialist markets. That includes molecularly defined acute leukemias, especially genetically segmented populations where targeted therapy can matter, and chronic graft-versus-host disease treated mainly at transplant centers and specialized hematology practices. Geographically, Syndax’s own commercial focus is centered on the United States, where a relatively small number of expert centers treat a meaningful share of eligible patients. The company is not trying to compete broadly across all solid tumors, all hematologic malignancies, or all inflammatory diseases.

3. 1c. How does Syndax plan to win?

   Syndax appears to plan to win through mechanism-based differentiation and concentrated execution. Revumenib is positioned around menin inhibition in biomarker-defined leukemia, while axatilimab is positioned around colony-stimulating factor 1 receptor biology in chronic graft-versus-host disease. That creates a value proposition based on clinical need, molecular relevance, and specialist adoption rather than mass-market promotion. Syndax also improves its odds by choosing indications where a relatively small commercial infrastructure can cover most important prescribers, and by using partnerships where those partnerships improve development or go-to-market economics.

4. 1d. What capabilities must Syndax have in place?

   To make this strategy work, Syndax needs strong translational and clinical-development capabilities, especially in biomarker-defined disease. It also needs regulatory execution, medical affairs depth, specialty market-access capabilities, pharmacovigilance, and reliable outsourced manufacturing. Because the relevant prescriber base is concentrated, Syndax must be good at account-level execution with academic cancer centers, leukemia specialists, and transplant programs. It also needs the ability to identify patients through testing pathways and referral networks, which is especially important for genetically segmented leukemia indications.

5. 1e. What management systems does Syndax require?

   Syndax needs management systems that fit a small but increasingly commercial organization: strict portfolio prioritization, launch dashboards, cash-runway planning, alliance governance for partnered assets, and quality systems that satisfy commercial pharmacovigilance and manufacturing requirements. The company also needs discipline in sequencing investments. For an emerging biotech, one of the most important management systems is deciding how much to spend on lifecycle studies, field force build-out, and supply-chain readiness without overextending the balance sheet before revenue fully scales.

2. What Are the Current Strategic Initiatives of Syndax?

Syndax’s current strategic initiatives reflect a company balancing launch execution with continued development. Recent public communications point to several priorities.

• Commercializing Revuforj in the United States. For Syndax, the revumenib launch is not just a product rollout; it is the build-out of a precision-hematology commercial model. That means educating leukemia centers, supporting biomarker awareness, ensuring access and reimbursement, and establishing prescribing familiarity in a narrow but influential specialist community.
• Executing the Niktimvo launch in chronic graft-versus-host disease. Axatilimab gives Syndax exposure to transplant-centered medicine, where account penetration, infusion logistics, and reimbursement support matter as much as product awareness. The company’s partnership structure helps broaden commercial reach while sharing execution responsibilities.
• Expanding revumenib beyond the first approved niche. Management has emphasized broader development opportunities for revumenib, particularly in additional genetically defined acute myeloid leukemia settings and in combination regimens. This matters because the approved population is strategically important but relatively small.
• Building lifecycle evidence around axatilimab. In chronic graft-versus-host disease, long-term franchise value depends on more than initial approval. Syndax needs physician confidence, real-world evidence, and potentially broader use across treatment lines or adjacent indications if data support that path.
• Scaling from development-stage processes to commercial-stage operations. Syndax is building market access, distribution, medical affairs, safety, and supply processes suited to marketed products while still running a development pipeline. That organizational transition is a major initiative in its own right.
• Maintaining capital discipline. Like most emerging biopharma companies, Syndax must fund launch investments and additional clinical studies without losing financial flexibility. Cost sequencing and partner economics therefore remain strategic issues, not just finance issues.

3. What Is the Business Model of Syndax?

What customers actually buy. Syndax sells specialty prescription medicines to treat severe, specialist-managed conditions. Physicians and treatment centers buy into the clinical value proposition; patients receive the therapy; and reimbursement is ultimately shaped by commercial insurers, government payers, and healthcare-system economics.

Revenue model. Syndax’s revenue model is a mix of direct product sales and collaboration-related economics. For a launch-stage biotech, that can include product revenue, milestone or other partnership revenue, and cost-sharing or profit-sharing effects depending on the asset and geography. This is a prescription-drug model, not a subscription, software, or pay-per-use model.

Recurring versus one-time economics. Product revenue is partly repeat-driven because patients may remain on therapy for meaningful periods if they respond and tolerate treatment. However, patient cohorts in rare oncology and chronic graft-versus-host disease are much smaller than in primary-care markets, so recurring revenue is driven more by continued dosing and a steady flow of diagnosed patients than by large installed bases. Collaboration milestones are more episodic and non-recurring.

How pricing power works. Syndax can have pricing power typical of specialty oncology and orphan-style indications if its products show clear clinical value and limited direct alternatives in the approved setting. That pricing power is never absolute. It is constrained by payer review, treatment guidelines, provider economics, and competitive agents that may serve as substitutes in adjacent patient groups.

Why business mix matters. The mix between wholly recognized product sales and partnered economics matters a great deal. A dollar of revenue from a fully controlled product is not the same economically as a dollar recognized under a collaboration arrangement. Over time, investors usually care not just about headline revenue but about gross-to-net dynamics, shared economics, and how much selling expense Syndax must carry itself.

What drives margin and cash generation. Gross margin depends on manufacturing cost, product mix, launch scale, and channel discounts. Operating margin is heavily affected by research and development spending, medical affairs, and launch-period selling, general, and administrative expense. Cash generation remains pressured during the build phase because Syndax is funding both commercialization and lifecycle development. In that sense, the company’s model is typical of an emerging biotech: strong value can be created long before free cash flow becomes consistently positive.

4. What Products and/or Services Does Syndax Sell?

Syndax does not sell services in the conventional sense. It sells specialty prescription medicines and supports those medicines with the medical affairs, patient-access, and lifecycle-development activities typical of a commercial-stage biotech.

• Revuforj (revumenib). Revumenib is an oral menin inhibitor positioned in genetically defined acute leukemia. It is strategically important because it gives Syndax a foothold in precision hematology and, if additional studies succeed, could expand beyond its initial approved population into broader acute myeloid leukemia opportunities.
• Niktimvo (axatilimab-csfr). Axatilimab is a monoclonal antibody for chronic graft-versus-host disease after multiple prior systemic therapies. This product matters not only for direct revenue potential but also because it places Syndax in transplant-centered medicine, where specialist account relationships and treatment-center execution are central.
• Lifecycle-development programs. For Syndax, additional studies are part of the product set. The company is trying to increase the value of each asset by moving into new patient subsets, earlier lines of therapy, or rational combinations rather than relying solely on one narrow approved indication.

The company’s most important offerings are clearly revumenib and axatilimab. Older epigenetic programs that once defined Syndax are no longer the main strategic story.

5. What Are the Key Competitors or Peers of Syndax?

Syndax’s competition is best understood by indication rather than by overall company size. In leukemia, it competes against targeted and combination regimens used in acute myeloid leukemia and related settings. In chronic graft-versus-host disease, it competes against established and emerging specialist therapies.

A reasonable external synthesis is that Syndax does not face one all-purpose rival. Instead, it competes in a series of narrow therapeutic battles where molecular testing, physician familiarity, and treatment sequencing matter more than consumer brand awareness.

6. What Is the Marketing Strategy of Syndax?

Syndax’s marketing strategy is specialist and science-led. This is not a consumer-advertising story. In rare hematology and chronic graft-versus-host disease, the important audiences are key opinion leaders, leukemia specialists, transplant physicians, pharmacists, nurse coordinators, and reimbursement decision-makers inside treatment centers.

The practical tools are medical education, congress visibility, publication of clinical data, account-level engagement, and patient-access support. For revumenib, molecular testing awareness and referral pathways matter because eligible patients must first be identified. For axatilimab, transplant-center education and infusion-economics support are particularly important because the prescriber base is narrow and concentrated.

Marketing therefore functions mainly as a supporting capability rather than the main source of competitive advantage. The real differentiator is the product data and the relevance of the mechanism. Marketing’s job is to make sure the right specialists understand where the therapy fits, how to access it, and which patients are most appropriate.

7. What Are the Key Customer Segments of Syndax?

• Leukemia specialists. Hematologists and oncologists treating relapsed or refractory acute leukemia are core customers for Revuforj. Many are based at academic medical centers or large regional oncology networks.
• Transplant centers and chronic graft-versus-host disease specialists. These centers are central for Niktimvo because chronic graft-versus-host disease is concentrated among physicians with deep transplant follow-up experience.
• Hospitals, infusion centers, and oncology networks. Provider organizations matter because they manage formulary access, site-of-care decisions, and reimbursement processes.
• Specialty pharmacies and specialty distributors. These intermediaries matter operationally because they help move product to patients and providers, manage benefits verification, and support adherence or fulfillment workflows.
• Payers. Commercial and government payers are not the prescribing customer, but they are essential economic gatekeepers because they influence coverage, prior authorization, and out-of-pocket burden.
• Patients and caregivers. In specialty oncology and chronic graft-versus-host disease, patient support and navigation can materially affect therapy initiation and persistence, even though the formal sale is not made directly to consumers.

Syndax is not broadly diversified across dozens of end markets. Its customer base is concentrated in a small number of high-acuity specialist channels, which creates both focus and concentration risk.

8. What Is the Sales Model of Syndax?

Syndax uses a focused specialty-pharma sales model built around a relatively small number of high-value accounts. That model is more targeted than the broad primary-care sales forces used by large pharmaceutical companies.

• Direct specialist selling. Syndax’s own commercial teams call on hematologists, oncologists, transplant specialists, pharmacists, and reimbursement stakeholders at priority accounts.
• Medical affairs support. Scientific exchange is critical in this model, so medical science liaisons and related medical-affairs functions are as important as traditional sales representatives.
• Channel variation by product. Revuforj, as an oral therapy, is likely to rely more heavily on specialty-pharmacy workflows and pharmacy-benefit access. Niktimvo, as an infused biologic, is more tied to buy-and-bill economics, hospital or infusion-center logistics, and medical-benefit reimbursement.
• Partnership-enabled reach. For axatilimab, Syndax’s collaboration structure broadens execution capacity relative to what the company would have on a fully standalone basis.

This channel structure affects growth and pricing in important ways. A concentrated account base makes it possible to be highly targeted, but it also means that execution at a limited number of centers can disproportionately influence early launch performance. It also creates clear consultant opportunities in account segmentation, field-force design, patient services, and reimbursement process improvement.

9. In What Geographies Does Syndax Operate?

Syndax is headquartered in Waltham, Massachusetts, and its commercial footprint is centered on the United States. That makes sense for a launch-stage biotech: the company’s own infrastructure is most relevant where it has approved products, reimbursement capabilities, and concentrated specialist demand.

Its broader operating reach extends beyond the United States through clinical trial sites, investigator networks, regulatory activity, and collaborations. Syndax’s international presence is therefore more development- and partnership-driven than office-heavy. The company does not disclose a large owned manufacturing or distribution network across many countries; instead, it relies on external partners for much of that footprint.

Geographically, Syndax is still more concentrated than diversified. Near-term performance depends heavily on U.S. launch execution, while international value creation is likely to come through additional approvals, partnerships, and evidence generation rather than through a large self-owned global sales organization.

10. Who Are the Owners of Syndax?

Syndax is a public company whose shares trade on Nasdaq under the ticker SNDX. As of recent SEC reporting, the company did not disclose a controlling shareholder. Ownership appears typical of a small-cap biopharma company: a mix of institutional investors, healthcare-focused funds, broad mutual funds and index managers, plus holdings by executives, directors, and retail shareholders.

11. How Is Syndax Organized?

Officially, Syndax reports as a single operating and reportable segment. Practically, however, the company is organized around a few critical operating layers.

• Commercial franchise execution. This includes product launch, account management, market access, reimbursement support, and patient services.
• Research and development. Clinical development, translational medicine, regulatory strategy, and portfolio prioritization remain central because Syndax’s long-term value still depends on additional indications, not just current labels.
• Medical, safety, and quality functions. These functions matter more after approval because commercial-stage pharmacovigilance and product-quality systems carry higher operating importance.
• Alliance management. The axatilimab collaboration requires governance mechanisms that sit alongside a more traditional functional organization.
• Corporate infrastructure. Finance, legal, human resources, investor relations, and business-development support remain lean but important in a company making the transition from development-stage to commercial-stage operations.

So while Syndax is legally simple, operationally it is managing two different realities at once: a launch organization and a biotech pipeline organization.

12. How Does Syndax Operate?

On a day-to-day basis, Syndax operates as an integrated biopharma developer and specialty-commercial organization with heavy use of external partners.

1. Asset development. The company prioritizes a small number of lead assets, designs studies, and works with investigators and regulators to move those assets through approval and label expansion.
2. Outsourced execution. Like many biotech companies, Syndax relies on contract research organizations (CROs), contract development and manufacturing organizations (CDMOs), central labs, and specialist service providers rather than owning a large internal industrial base.
3. Regulatory and quality management. Syndax manages submissions, label maintenance, adverse-event reporting, and product-quality oversight.
4. Commercial launch execution. The company identifies priority accounts, supports reimbursement, moves product through specialty channels, and coordinates field teams with medical affairs.
5. Lifecycle management. Approved products are not the endpoint. Syndax continues to run studies designed to expand indications, deepen physician confidence, and improve the value of each franchise.

The main operational complexities are patient identification, channel orchestration, and capital discipline. In a rare leukemia indication, finding the right patient quickly can matter as much as selling the drug. In chronic graft-versus-host disease, transplant-center workflows and reimbursement can be decisive. And because Syndax is still scaling, it must do all of this without building more infrastructure than the revenue base can support.

13. What Are the Growth Opportunities for Syndax?

The most plausible growth opportunities for Syndax fall into five categories.

• Deeper penetration of currently approved indications. Early launch execution can improve as physician familiarity, payer access, and patient-identification processes mature.
• Revumenib label expansion. This is likely the most important medium-term opportunity. Management has pointed to broader use in additional genetically defined acute myeloid leukemia populations and in combination regimens.
• Axatilimab franchise development. Niktimvo can grow through stronger penetration of chronic graft-versus-host disease treatment centers and, if supported by data and regulators, through additional lifecycle expansion.
• International value capture. Syndax’s pipeline and approved assets could create more value outside the United States through partnerships or expanded geographic approvals.
• Selective business development. A reasonable external view is that Syndax could eventually add adjacent hematology or oncology assets if they fit its specialist commercial model.

The main constraints are equally clear: rare-disease market size, the need for biomarker testing, competition from other targeted agents and established regimens, manufacturing and supply reliability, and the balance-sheet demands of launch-period investment. In other words, Syndax’s opportunity set is real, but it depends on very good execution in a relatively narrow field.

14. What Is the History of Syndax?

Syndax was founded in 2005 and is based in Massachusetts. For much of its earlier history, the company was known primarily as an oncology biotech focused on epigenetic approaches, especially the histone deacetylase inhibitor entinostat. Syndax went public in 2015, giving it access to public-market capital typical of development-stage biotech companies.

A major turning point came when entinostat failed to deliver the hoped-for outcome in a late-stage breast-cancer study, forcing a strategic reset. That mattered because it pushed Syndax away from being largely identified with one epigenetic program and toward a more focused portfolio built around newer assets with stronger strategic fit.

In the early 2020s, Syndax repositioned around two programs that now define the company: revumenib in genetically defined acute leukemia and axatilimab in chronic graft-versus-host disease. Those moves shifted Syndax toward hematology, transplant medicine, and precision oncology. The next major milestone came in 2024, when the company achieved its first U.S. product approvals and effectively crossed from clinical-stage biotech into commercial-stage specialty pharma.

15. What Are the Key Suppliers to Syndax?

Suppliers are strategically important to Syndax because the company relies heavily on external partners rather than on a large owned manufacturing base.

• CDMOs. Contract development and manufacturing organizations supply active pharmaceutical ingredients, biologic drug substance, fill-finish services, packaging, labeling, and release support.
• CROs and central labs. These partners support trial execution, data management, biomarker testing, and specialized analytics.
• Specialty distribution and pharmacy partners. They help move product to hospitals, infusion centers, and patients while managing fulfillment and reimbursement workflows.
• Raw-material and component suppliers. For both small molecules and biologics, single-source or limited-source inputs can create continuity risk.
• Specialist service vendors. Pharmacovigilance, quality, regulatory support, and patient-services vendors can also be important during the commercial build-out.

Syndax does not publicly emphasize a broad roster of named suppliers in the way a manufacturer or retailer might. What matters strategically is the structure: concentrated outsourced dependencies, long lead times, and the need for high regulatory compliance.

16. How Does the Supply Chain of Syndax Function?

Syndax’s supply chain is typical of a modern specialty-biopharma company: asset-light physically, but operationally demanding.

Revuforj supply chain. As an oral small-molecule therapy, revumenib’s chain likely runs from active-ingredient production to drug-product manufacturing, packaging, quality release, specialty distribution, and specialty-pharmacy fulfillment. The key issues are reliability, lot release, and getting product to eligible patients quickly once prescribing decisions are made.

Niktimvo supply chain. Axatilimab, as a biologic, has a more sensitive chain involving biologic manufacturing, fill-finish, cold-chain handling, and delivery to provider sites that administer infused therapy. Here, temperature control, scheduling, and site-of-care coordination are critical.

Why this matters. In rare diseases and acute care settings, a stockout or administrative delay matters more than it might in a large primary-care market. Demand can be hard to forecast, but service levels must still be high. That makes forecasting, inventory policy, quality oversight, and distributor coordination strategic issues rather than back-office details.

17. What Are the Key Assets of Syndax?

Syndax’s key assets are mostly intangible rather than physical.

• Approved products and related rights. Revumenib and axatilimab are the core value drivers.
• Intellectual property and regulatory exclusivity. Patent estate, know-how, manufacturing data, and exclusivity periods are essential to protecting economics in a specialist market.
• Clinical data packages. Regulatory approvals in biotech are built on data, and those data packages are strategic assets because they support labeling, payer discussions, and future expansion studies.
• Partnership structures. The Incyte collaboration is a meaningful asset because it can improve development and commercialization leverage.
• Cash and access to capital markets. For an emerging biotech, liquidity is an operating asset. It determines how aggressively the company can fund launches and additional trials.
• Specialist-center relationships. Access to leading leukemia and transplant centers is a practical asset because these centers influence adoption, guidelines, and future studies.

Syndax is not asset-heavy in the factory, fleet, or infrastructure sense. Its value is concentrated in molecules, data, rights, and the ability to execute around them.

18. What Is the R&D Strategy of Syndax?

R&D is central to Syndax’s strategy because the company’s current approved indications are important but narrow. Long-term value depends on turning each lead asset into a broader franchise.

The company’s R&D approach appears focused rather than platform-wide. Syndax is not trying to run a sprawling discovery engine across many targets. Instead, it concentrates capital on a limited number of assets with clear biologic rationale, clinically identifiable patient groups, and visible regulatory pathways. That is a rational model for a company of Syndax’s size.

For revumenib, the R&D logic is to establish value in a clearly defined leukemia subset and then expand outward into additional mutation-defined populations and combinations. For axatilimab, the logic is to use approved chronic graft-versus-host disease positioning as the base for deeper clinical evidence and possible lifecycle broadening. In both cases, translational science, biomarker strategy, and careful trial sequencing matter more than sheer portfolio breadth.

A useful way to think about Syndax’s R&D strategy is this: prove the mechanism in a narrow setting, win approval where differentiation is strongest, then use that credibility to move into larger or earlier opportunities.

19. What Is the Finance Strategy of Syndax?

Syndax’s finance strategy is typical of an emerging commercial-stage biotech: preserve liquidity, fund the highest-value clinical and launch activities, and use partnership structures where they reduce standalone capital needs.

The company does not operate like a mature cash-return story. There is no investment case built around dividends or buybacks. Instead, capital allocation is directed toward four priorities: supporting launch execution, funding lifecycle-development trials, maintaining manufacturing and supply readiness, and preserving enough balance-sheet flexibility to absorb the uneven cash profile of early commercialization.

Collaboration economics are part of that strategy. Partnering can reduce the burden of funding development and commercialization entirely alone, even if it also limits the share of economics retained. For Syndax, that trade-off can be sensible because execution risk and capital intensity are both meaningful.

From an evergreen perspective, the key financial question is not whether Syndax is already producing mature pharmaceutical margins. It is whether management is allocating capital in a way that turns two approved assets into larger, more durable franchises without forcing avoidable dilution or underinvestment.

20. How Companies Like Syndax Leverage Independent Consultants through Umbrex

Umbrex has grown a global community of more than 8,000 independent management consultants based in over 50 countries. These consultants are alumni of McKinsey, Bain, BCG, and other top consulting firms. Companies like Syndax use Umbrex when they need top-tier problem solving in strategy, operations, organization, marketing, sales, finance, technology, ERP, or AI, but do not need a full consulting team with the overhead of a traditional firm. For a launch-stage biotech such as Syndax, the most useful projects are usually highly targeted, time-sensitive, and cross-functional.

• Rare-disease launch readiness assessment for Revuforj and Niktimvo, including account prioritization, bottleneck diagnosis, and operating cadence design
• Market-access strategy for a dual-channel portfolio, with separate recommendations for oral specialty-pharmacy reimbursement and infused buy-and-bill economics
• Leukemia center and transplant-center segmentation, including key opinion leader mapping, referral-pattern analysis, and field-force territory design
• Biomarker testing and patient-identification strategy for genetically defined acute leukemia populations, including lab-network and pathway analysis
• Commercial operating-model design for a small specialty field organization, including role clarity across sales, medical affairs, market access, and patient services
• Alliance-governance review for partnered assets, helping improve decision rights, launch coordination, and conflict resolution across Syndax and partner teams
• CDMO and supply-chain risk assessment, including inventory policy, dual-sourcing options, quality-governance design, and launch-scale forecasting
• Lifecycle portfolio prioritization across revumenib and axatilimab studies, helping management allocate capital across indications, combinations, and geographies
• Commercial analytics build-out, including dashboard design for new-to-brand prescriptions, account activation, patient-start conversion, and access friction
• Business-development landscaping in adjacent hematology and oncology niches to identify assets that fit Syndax’s focused specialist-commercial model